Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Nilotinib + Imatinib in CML
NCT01819389Phase 3Completed
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Start
- Oct 2012
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of nilotinib and imatinib in chronic myeloid leukemia (CML), sponsored by Hospital Universitario Dr. Jose E. Gonzalez. Primary endpoint: Major Molecular Response at 6 months. Started Oct 2012; status: completed.
02
Drugs
nilotinibimatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01819389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01819389.